Literature DB >> 28501576

Liraglutide, a glucagon-like peptide-1 analog, induce autophagy and senescence in HepG2 cells.

Gabriele Catyana Krause1, Kelly Goulart Lima2, Henrique Bregolin Dias2, Elisa Feller Gonçalves da Silva2, Gabriela Viegas Haute2, Bruno Souza Basso2, Rodrigo Benedetti Gassen3, Elisa Simon Marczak3, Rafaela Sole Bach Nunes2, Jarbas Rodrigues de Oliveira4.   

Abstract

It has been reported that glucagon-like peptide-1 (GLP-1) agents have been associated with both the increased risk of cancer and inhibition of tumor growth and metastases. The aim of this study is to evaluate the effect of liraglutide on hepatocellular carcinoma cells - HepG2. Cytometry was used to evaluate mechanism related to decreased cell proliferation. Nuclear staining and morphometric analysis were also used to verify the process that was taking place after treatment with liraglutide, and in order to better understand the mechanism, TGF-β1 was performed. HepG2 cells decreased proliferation after liraglutide treatment without altering oxidative stress levels. Liraglutide was able to induce autophagy and senescence through the increase of TGF-β1 which possibly explains the growth decrease. We have demonstrated that liraglutide has an antiproliferative effect in HepG2 cells inducing autophagy and senescence by the increase of TGF-β1.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autophagy; HepG2; Hepatocellular carcinoma; Liraglutide; Senescence; TGF-β1

Mesh:

Substances:

Year:  2017        PMID: 28501576     DOI: 10.1016/j.ejphar.2017.05.015

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Renoprotective Effect of Liraglutide Is Mediated via the Inhibition of TGF-Beta 1 in an LLC-PK1 Cell Model of Diabetic Nephropathy.

Authors:  Vjera Ninčević; Milorad Zjalić; Tea Omanović Kolarić; Martina Smolić; Tomislav Kizivat; Lucija Kuna; Aleksandar Včev; Ashraf Tabll; Ines Bilić Ćurčić
Journal:  Curr Issues Mol Biol       Date:  2022-02-25       Impact factor: 2.976

2.  MicroRNA-21 promotes the proliferation, migration and invasion of non-small cell lung cancer A549 cells by regulating autophagy activity via AMPK/ULK1 signaling pathway.

Authors:  Shuping Li; Xiaofei Zeng; Ruidong Ma; Li Wang
Journal:  Exp Ther Med       Date:  2018-06-29       Impact factor: 2.447

3.  Exenatide induces autophagy and prevents the cell regrowth in HepG2 cells.

Authors:  Gabriele Catyana Krause; Kelly Goulart Lima; Vitor Levorse; Gabriela Viegas Haute; Rodrigo Benedetti Gassen; Maria Cláudia Garcia; Leonardo Pedrazza; Márcio Vinícius Fagundes Donadio; Carolina Luft; Jarbas Rodrigues de Oliveira
Journal:  EXCLI J       Date:  2019-07-22       Impact factor: 4.068

4.  Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1/2 pathway.

Authors:  Ya-Ru Wu; Xiao-Yun Shi; Chun-Yan Ma; Yue Zhang; Rui-Xia Xu; Jian-Jun Li
Journal:  Cardiovasc Diabetol       Date:  2019-11-09       Impact factor: 9.951

Review 5.  How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma.

Authors:  Konstantinos Arvanitakis; Theocharis Koufakis; Kalliopi Kotsa; Georgios Germanidis
Journal:  Cancers (Basel)       Date:  2022-09-24       Impact factor: 6.575

6.  Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism.

Authors:  Sheng-Hua Yang; Rui-Xia Xu; Chuan-Jue Cui; Yin Wang; Ying Du; Zhi-Guo Chen; Yu-Hong Yao; Chun-Yan Ma; Cheng-Gang Zhu; Yuan-Lin Guo; Na-Qiong Wu; Jing Sun; Bu-Xing Chen; Jian-Jun Li
Journal:  Cardiovasc Diabetol       Date:  2018-04-04       Impact factor: 9.951

Review 7.  Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention.

Authors:  Danny Orabi; Nathan A Berger; J Mark Brown
Journal:  Cancers (Basel)       Date:  2021-07-11       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.